As first‐line drugs for treating EGFR‐mutated NSCLC, afatinib and the third‐generation TKI osimertinib have been shown to be feasible for treating NSCLC patients with several active mutation sites, especially T790M‐positive EGFR mutation‐positive patients [23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.